Linda E. Kelemen

South Carolina Department of Health and Environmental Control — United States

Medicine · Health Sciences

45h-index7.7kcitations322works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(178), PARP inhibition in cancer therapy(35), RNA modifications and cancer(33), Cancer-related molecular mechanisms research(21), Folate and B Vitamins Research(16)

Publications312 total

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Adult Day Care in South Carolina: Identification of Need and Opportunity
Journal of the American Medical Directors Association·2024
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Journal of Clinical Investigation·2024· 13 citedOpen Access
Supplementary Figure S10 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Table S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Figure S8 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Figure 1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Figure S6 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Table S2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Table S20 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
Supplementary Table S15 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
2024Open Access
page 1 of 16Next →

Frequent Co-authors

Ellen L. Goode(26), Marc T. Goodman(19), Estrid Høgdall(19), Robert A. Vierkant(19), Brooke L. Fridley(18), Martin Köbel(18), Julie M. Cunningham(17), Aleksandra Gentry‐Maharaj(17), Linda S. Cook(16), Susanne K. Kjær(16), Susan J. Ramus(16), Ian Campbell(15), Daniel W. Cramer(15), Claus Høgdall(15), Allan Jensen(15), Beth Y. Karlan(15), Diether Lambrechts(15), Jan Lubiński(15), Roberta B. Ness(15), Jennifer A. Doherty(14)